63 F
New York
Friday, September 25, 2020

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Stock Moves out of The Trading Zone on Wednesday

Must read

The Forecast Just Changed on Owens & Minor Inc. (NYSE:OMI)

Owens & Minor Inc. (OMI) shares are trading at higher $20.31 and the avg recommendation for the stock is Moderate Buy, while the current...

Kinross Gold Corporation (NYSE:KGC) is Holding Steady

Kinross Gold Corporation (KGC) shares are trading at higher $8.84 and the avg recommendation for the stock is Moderate Buy, while the current analyst...

Snap Inc. (NYSE:SNAP) Recent Earnings Shows Major Concern

Snap Inc. (SNAP) shares are trading at lower $24.32 and the avg recommendation for the stock is Moderate Buy, while the current analyst price...

Barrick Gold Corporation (NYSE:GOLD) is Waving the Bull Flag

Barrick Gold Corporation (GOLD) shares are trading at higher $27.65 and the avg recommendation for the stock is Moderate Buy, while the current analyst...

Pharmaceutical stocks have performed quite impressively in recent times and over the past few months; many new stocks have emerged that have garnered attention from investors. One of the pharmaceutical stocks to have emerged as a winner on Wednesday is that of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), which surged by as much as 9% on Wednesday on the back of major development with regards to one of its products.

A Major Development

Yesterday, it emerged that Aurinia Pharma’s New Drug Application for its product voclosporin, has been accepted by the United States Food and Drug Administration. It is a significant development for the company and the reaction from investors in Wednesday trading was understandable.

The product in question is meant for treating lupus nephritis, which is a critical inflammation of the patient’s kidneys brought about by the autoimmune disease systemic lupus erythematosus (SLE). However, more importantly, the FDA actually granted Aurinia a priority review in only 6 months. It is a major coup for the company since a priority review usually takes place in 10 months.

A PDUFA decision date for the same has been set by the agency for January 21 next year. In addition to that, the company was also informed by the FDA that at this time it is not planning to have an advisory committee meeting regarding the application.

The Chief Executive Officer of the company, Peter Greenleaf, stated that Aurinia is going to continue to collaborate with the agency during the course of the review process.

Concurrently, the company is going to work on its readiness for a commercial launch if the approval is granted by the FDA in the first fiscal quarter of 2021. Voclosporin is a potentially best in class treatment for the ailment in question and that is supported by data gleaned from across 2600 patients. The latest development could bring the stock in the radars of investors over the coming days. Sign up below for breakout alerts and updates on fast moving stocks.

Latest article

Investor Confidence is Falling for Nordstrom Inc. (NYSE:JWN)

Nordstrom Inc. (JWN) shares are trading at lower $12.12 and the avg recommendation for the stock is Hold, while the current analyst price target...

MGM Resorts International (NYSE:MGM) is Gaining Momentum on Earnings Catalyst

MGM Resorts International (MGM) shares are trading at lower $21.19 and the avg recommendation for the stock is Moderate Buy, while the current analyst...

The Rejuvenation of Virgin Galactic Holdings Inc. (NYSE:SPCE)

Virgin Galactic Holdings Inc. (SPCE) shares are trading at higher $15.92 and the avg recommendation for the stock is Moderate Buy, while the current...

General Motors Company (NYSE:GM) Recent Earnings Shows Major Concern

General Motors Company (GM) shares are trading at lower $29.11 and the avg recommendation for the stock is Strong Buy, while the current analyst...

The Unprecedented Rise of NIKE Inc. (NYSE:NKE)

NIKE Inc. (NKE) shares are trading at lower $124.75 and the avg recommendation for the stock is Moderate Buy, while the current analyst price...